Clinical Trial Testing the Safety of Four Ramucirumab Doses Given as Second Line Treatment to Patients with Stomach Cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-003791-23

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

Evaluate ramucirumab PK following various dose regimens. Assess the safety for each dose group of ramucirumab in patients with advanced gastric cancer, whose disease has progressed during or following prior combination chemotherapy


Critère d'inclusion

  • Second Line Gastric or Gastroesophageal Junction Adenocarcinoma